Answers are grounded in this paper and cite their sources.
The BNT162b2 vaccine is effective in high-risk real-life exposure scenarios, but the protection afforded in these settings is lower than that previously described. Individuals with a confirmed significant exposure to severe acute respiratory syndrome are still at risk of being infected even if fully vaccinated.
No takes yet. Share an insight, caveat, or question.
Gazit et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: